A study in Hematopoietic Stem Cell Transplant patients
15/06/2015 - This retrospective cohort study determined an appropriate empiric oral sirolimus dose adjustment when given concurrently with posaconazole oral suspension in 75 patients who undergo hematopoietic stem cell transplant (HSCT). It was determined that coadministration of posaconazole oral suspension with oral sirolimus increases the sirolimus C/D ratio by approximately 2.7-fold in HSCT patients. An initial empiric oral sirolimus dose reduction between 50% and 65% may be recommended for most clinically stable patients with close sirolimus concentration monitoring for at least 3 weeks following posaconazole initiation.
Management of Drug Interaction between Posaconazole and Sirolimus in Patients Who Undergo Hematopoietic Stem Cell Transplant
Cho E, Chan H, Nguyen HM, Shayani S, Nakamura R, Pon D.
Pharmacotherapy. 2015 Jun 3. doi: 10.1002/phar.1600.
Find this article here